Browse by Series:

FDA Approval of Durvalumab for Stage III Unresectable NSCLC

Gina Columbus
Published: Friday, Feb 16, 2018



Hello and welcome to OncLive News Network, Breaking News. I'm Gina Columbus.

The FDA has approved the PD-L1 inhibitor durvalumab (Imfinzi) for the treatment of patients with stage III, unresectable non-small cell lung cancer. The indication is for patients whose disease has not progressed following platinum-based chemoradiation therapy.

The decision was based on positive progression-free survival (PFS) results from the phase III PACIFIC trial, in which the median PFS from randomization showed an 11.2-month benefit associated with durvalumab versus placebo at 16.8 months vs 5.6 months, respectively. The 12-month PFS rate was 55.9% versus 35.3%, and the 18-month PFS rate was 44.2% versus 27.0%, again favoring the durvalumab arm.

Investigators found a PFS benefit associated with durvalumab was consistent across all pre-specified subgroups, and the PFS benefit was also held irrespective of PD-L1 expression before chemoradiotherapy.

Objective response rate was also significantly higher with durvalumab at 28.4% vs 16.0% with placebo. In addition, 16.5% of patients in the durvalumab group experienced disease progression compared with 27.7% of the placebo arm.

For more breaking news, subscribe to email alerts from OncLive.com. Thank you for watching! I'm Gina Columbus.
Slider Left
Slider Right


Hello and welcome to OncLive News Network, Breaking News. I'm Gina Columbus.

The FDA has approved the PD-L1 inhibitor durvalumab (Imfinzi) for the treatment of patients with stage III, unresectable non-small cell lung cancer. The indication is for patients whose disease has not progressed following platinum-based chemoradiation therapy.

The decision was based on positive progression-free survival (PFS) results from the phase III PACIFIC trial, in which the median PFS from randomization showed an 11.2-month benefit associated with durvalumab versus placebo at 16.8 months vs 5.6 months, respectively. The 12-month PFS rate was 55.9% versus 35.3%, and the 18-month PFS rate was 44.2% versus 27.0%, again favoring the durvalumab arm.

Investigators found a PFS benefit associated with durvalumab was consistent across all pre-specified subgroups, and the PFS benefit was also held irrespective of PD-L1 expression before chemoradiotherapy.

Objective response rate was also significantly higher with durvalumab at 28.4% vs 16.0% with placebo. In addition, 16.5% of patients in the durvalumab group experienced disease progression compared with 27.7% of the placebo arm.

For more breaking news, subscribe to email alerts from OncLive.com. Thank you for watching! I'm Gina Columbus.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Management of Adverse Events Associated with Therapies for Hematological Disorders: Nurses' PerspectiveApr 21, 20182.0
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Publication Bottom Border
Border Publication
x